- Latest Stories
- Commentary and Analysis
10:14AM ET 3/31/2022 MT NewswiresOutlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational...
5:45PM ET 2/23/2022 MT NewswiresKurt J Hilzinger, Director, on February 22, 2022, executed a purchase for 175,132 shares in Outlook Therapeutics (OTLK) for $256,970. Following the Form 4...
10:26AM ET 12/27/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
6:18AM ET 12/02/2021 MT NewswiresGhiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....
6:14AM ET 11/24/2021 MT NewswiresOutlook Therapeutics (OTLK) on Tuesday increased its previously announced bought-deal offering of common shares to $50 million in gross proceeds from the...
4:51PM ET 11/23/2021 MT NewswiresOutlook Therapeutics (OTLK) said late Tuesday it agreed to a bought-deal offering of common stock allowing underwriter HC Wainwright to buy 8 million...
3:30PM ET 10/12/2021 MT NewswiresOutlook Therapeutics (OTLK) said Tuesday its ophthalmic formulation of bevacizumab for retinal indications produced "strong" safety data consistent with...
10:30AM ET 9/28/2021 MT NewswiresOutlook Therapeutics (OTLK) said Tuesday its ONS-5010 drug being developed for the potential treatment of age-related macular degeneration showed its...
10:38AM ET 8/03/2021 MT NewswiresOutlook Therapeutics (OTLK) said Tuesday that ONS-5010 met both of its primary and secondary endpoints in a phase 3 trial in patients with neovascular...
9:13AM ET 8/03/2021 MT NewswiresUS stocks were set for a cautiously higher open Tuesday, staging a slight recovery after tumbling in the previous session as US manufacturing sentiment...